NeuroPace Inc. (NPCE)
12.41
-0.31 (-2.44%)
At close: Mar 27, 2025, 3:59 PM
12.38
-0.23%
After-hours: Mar 27, 2025, 04:33 PM EDT
-2.44% (1D)
| Bid | 12 |
| Market Cap | 404.01M |
| Revenue (ttm) | 86.97M |
| Net Income (ttm) | -29.54M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -12.66 |
| Forward PE | -15.68 |
| Analyst | Buy |
| Ask | 13.47 |
| Volume | 217,252 |
| Avg. Volume (20D) | 232,018 |
| Open | 12.67 |
| Previous Close | 12.72 |
| Day's Range | 12.09 - 12.74 |
| 52-Week Range | 5.45 - 15.78 |
| Beta | 2.07 |
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilitie...
Industry Medical - Devices
Sector Healthcare
IPO Date Apr 22, 2021
Employees 184
Stock Exchange NASDAQ
Ticker Symbol NPCE
Website https://www.neuropace.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 37.01% from the latest price.
Stock ForecastsNext Earnings Release
NeuroPace Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+9.11%
Neurospace shares are trading higher after UBS ini...
Unlock content with
Pro Subscription
4 months ago
+28.15%
Neuropace shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Wells Fargo maintained an Overweight rating on the stock.
